Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
100%
Adverse Event
90%
Malignant Neoplasm
70%
Methylphenidate
60%
Pharmacogenetics
60%
Acenocoumarol
60%
Antiinfective Agent
60%
Case-Control Study
60%
Observational Study
60%
Metoprolol
60%
Dipeptidyl Carboxypeptidase Inhibitor
60%
Non Small Cell Lung Cancer
60%
Progression Free Survival
55%
Cohort Study
49%
Pharmacotherapy
45%
Overall Survival
42%
Phenprocoumon
42%
Coughing
38%
Infection
35%
Anticoagulant Agent
35%
Drug-Drug Interaction
30%
Pharmacoepidemiology
30%
Advanced Cancer
30%
Kidney Metastasis
30%
Clozapine
30%
Apolipoprotein E
30%
Sunitinib
30%
Life Expectancy
30%
Hypokalemia
30%
Pazopanib
30%
Vitamin D
30%
Remdesivir
30%
Flucloxacillin
30%
Hyponatremia
30%
Programmed Cell Death
30%
Disease Exacerbation
30%
Frailty
30%
Diuretics
30%
Fluoropyrimidine
30%
Lung Cancer
30%
Diseases
26%
Cholecalciferol
24%
Captopril
23%
Enalapril
23%
Nivolumab
22%
Polypharmacy
20%
Congestive Heart Failure
20%
Chemotherapy
18%
Neoplasm
17%
Isotopes of Potassium
15%
Medicine and Dentistry
Odds Ratio
63%
Observational Study
60%
ACE Inhibitor
60%
Case-Control Study
60%
Progression Free Survival
42%
Overall Survival
42%
Coughing
38%
Adverse Event
38%
Drug Therapy
34%
Adverse Drug Reaction
34%
Pharmacogenetics
30%
Outpatient
30%
Infection
30%
Anaphylaxis
30%
Chlorhexidine
30%
Hyponatremia
30%
Antimicrobial Therapy
30%
Kidney Metastasis
30%
Life Expectancy
30%
Advanced Cancer
30%
Glycon
30%
Simvastatin
30%
Clinical Trial
30%
Cardiovascular Disease
30%
Programmed Death-Ligand 1
30%
Cardiovascular System
30%
Cardiology
30%
Non Small Cell Lung Cancer
30%
Sunitinib
30%
General Medicine
30%
Pazopanib
30%
Immune-Related Adverse Events
30%
Diuretics
30%
Programmed Cell Death
30%
Oncologist
30%
Infectious Disease
25%
General Practitioner
23%
Nivolumab
22%
Electronic Health Record
20%
Polypharmacy
20%
Enalapril
18%
Captopril
18%
Intervention Trial
15%
Cardiovascular Agent
15%
Programmed Death 1 Ligand 1
15%
Ipilimumab
15%
Antibiotic Therapy
12%
Drug Administration Route
12%
Hospital Information System
11%
Narcotic Analgesic Agent
10%
Nursing and Health Professions
Odds Ratio
38%
Life Expectancy
30%
Vitamin D
30%
Chlorhexidine
30%
Supplementation
30%
Urethral Catheterization
30%
Anaphylaxis
30%
Dipeptidyl Carboxypeptidase Inhibitor
30%
Advanced Cancer
30%
Coughing
30%
Hyponatremia
30%
Body Mass
30%
Case-Control Study
30%
Patient with Hypertension
30%
Adverse Event
30%
Disease Exacerbation
30%
Electronic Health Record
30%
Non Small Cell Lung Cancer
30%
Frailty
30%
Oncologist
30%
Polypharmacy
20%
Colecalciferol
15%
General Practitioner
15%
Progression Free Survival
12%
Catheterization
10%
Enalapril
10%
Lubricating Agent
10%
Cystoscopy
10%
Captopril
10%
Prevalence
10%
Patient Satisfaction
10%
Malignant Neoplasm
10%
Geriatrician
10%
Antihypertensive Agent
10%
Narcotic Analgesic Agent
10%
Care Pathway
10%
Gender Difference
8%
Kaplan Meier Method
6%
Diseases
6%
Emphysema
5%
Chronic Bronchitis
5%
Laryngitis
5%
Respiratory Tract Infection
5%
Hemoptysis
5%
Neoplasm
5%
Congestive Heart Failure
5%
Asthma
5%
Sinusitis
5%
